| __timestamp | Alkermes plc | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 447875000 | 9335772 |
| Thursday, January 1, 2015 | 483393000 | 999000 |
| Friday, January 1, 2016 | 519270000 | 978000 |
| Sunday, January 1, 2017 | 567637000 | 952000 |
| Monday, January 1, 2018 | 601826000 | 956000 |
| Tuesday, January 1, 2019 | 693218000 | 8122999 |
| Wednesday, January 1, 2020 | 572904000 | 8712000 |
| Friday, January 1, 2021 | 603913000 | 13980000 |
| Saturday, January 1, 2022 | 218108000 | 21135000 |
| Sunday, January 1, 2023 | 253037000 | 10755000 |
| Monday, January 1, 2024 | 245331000 |
Unleashing the power of data
In the ever-evolving landscape of biotechnology, cost efficiency remains a pivotal factor for success. This analysis delves into the cost of revenue trends for Alkermes plc and Iovance Biotherapeutics, Inc. from 2014 to 2023. Over this period, Alkermes plc consistently reported higher costs, peaking in 2019 with a 39% increase from 2014. In contrast, Iovance Biotherapeutics, Inc. maintained a leaner cost structure, with costs remaining relatively stable until a notable rise in 2022. This divergence highlights Alkermes' expansive operational scale compared to Iovance's focused approach. The data suggests that while Alkermes invests heavily in its operations, Iovance's strategy leans towards cost containment. As the biotech sector continues to grow, understanding these cost dynamics offers valuable insights into each company's strategic priorities and market positioning.
Cost of Revenue: Key Insights for Eli Lilly and Company and Iovance Biotherapeutics, Inc.
Novo Nordisk A/S vs Alkermes plc: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Merck & Co., Inc. and Alkermes plc's Expenses
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Alkermes plc
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Alkermes plc
Comparing Cost of Revenue Efficiency: Grifols, S.A. vs Iovance Biotherapeutics, Inc.
Corcept Therapeutics Incorporated vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Alkermes plc vs Veracyte, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Alkermes plc and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Comparison: HUTCHMED (China) Limited vs Iovance Biotherapeutics, Inc.